Cargando…

Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project

The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public–private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmona, Antonio, Muñoz-Quiles, Cintia, Stuurman, Anke, Descamps, Alexandre, Mira-Iglesias, Ainara, Torcel-Pagnon, Laurence, Díez-Domingo, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908420/
https://www.ncbi.nlm.nih.gov/pubmed/33504081
http://dx.doi.org/10.3390/ijerph18031058
_version_ 1783655709634723840
author Carmona, Antonio
Muñoz-Quiles, Cintia
Stuurman, Anke
Descamps, Alexandre
Mira-Iglesias, Ainara
Torcel-Pagnon, Laurence
Díez-Domingo, Javier
author_facet Carmona, Antonio
Muñoz-Quiles, Cintia
Stuurman, Anke
Descamps, Alexandre
Mira-Iglesias, Ainara
Torcel-Pagnon, Laurence
Díez-Domingo, Javier
author_sort Carmona, Antonio
collection PubMed
description The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public–private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative). It was initiated as a response to the guidance on influenza vaccines by EMA (European Medicines Agency), which advised vaccine manufacturers to work with public health institutes to set up a joint IVE study platform. The COVID-19 pandemic reached Europe in February 2020 and overlapped with the 2019/2020 influenza season only in the last weeks. However, several elements of the DRIVE study network were impacted. The pandemic specifically affected the study sites’ routines and the subsequent assessment of the 2019/20 influenza season. Moreover, the current social distancing measures and lockdown policies across Europe are expected to also limit the circulation of influenza for the 2020/21 season, and therefore the impact of COVID-19 will be higher than in the season 2019/20. Consequently, DRIVE has planned to adapt its study platform to the COVID-19 challenge, encompassing several COVID-19 particularities in the study procedures, data collection and IVE analysis for the 2020/21 season. DRIVE will study the feasibility of implementing these COVID-19 components and establish the foundations of future COVID-19 vaccine effectiveness studies.
format Online
Article
Text
id pubmed-7908420
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79084202021-02-27 Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project Carmona, Antonio Muñoz-Quiles, Cintia Stuurman, Anke Descamps, Alexandre Mira-Iglesias, Ainara Torcel-Pagnon, Laurence Díez-Domingo, Javier Int J Environ Res Public Health Article The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public–private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative). It was initiated as a response to the guidance on influenza vaccines by EMA (European Medicines Agency), which advised vaccine manufacturers to work with public health institutes to set up a joint IVE study platform. The COVID-19 pandemic reached Europe in February 2020 and overlapped with the 2019/2020 influenza season only in the last weeks. However, several elements of the DRIVE study network were impacted. The pandemic specifically affected the study sites’ routines and the subsequent assessment of the 2019/20 influenza season. Moreover, the current social distancing measures and lockdown policies across Europe are expected to also limit the circulation of influenza for the 2020/21 season, and therefore the impact of COVID-19 will be higher than in the season 2019/20. Consequently, DRIVE has planned to adapt its study platform to the COVID-19 challenge, encompassing several COVID-19 particularities in the study procedures, data collection and IVE analysis for the 2020/21 season. DRIVE will study the feasibility of implementing these COVID-19 components and establish the foundations of future COVID-19 vaccine effectiveness studies. MDPI 2021-01-25 2021-02 /pmc/articles/PMC7908420/ /pubmed/33504081 http://dx.doi.org/10.3390/ijerph18031058 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Carmona, Antonio
Muñoz-Quiles, Cintia
Stuurman, Anke
Descamps, Alexandre
Mira-Iglesias, Ainara
Torcel-Pagnon, Laurence
Díez-Domingo, Javier
Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project
title Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project
title_full Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project
title_fullStr Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project
title_full_unstemmed Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project
title_short Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the COVID-19 Emergence: Experience from the DRIVE Project
title_sort challenges and adaptation of a european influenza vaccine effectiveness study platform in response to the covid-19 emergence: experience from the drive project
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908420/
https://www.ncbi.nlm.nih.gov/pubmed/33504081
http://dx.doi.org/10.3390/ijerph18031058
work_keys_str_mv AT carmonaantonio challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject
AT munozquilescintia challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject
AT stuurmananke challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject
AT descampsalexandre challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject
AT miraiglesiasainara challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject
AT torcelpagnonlaurence challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject
AT diezdomingojavier challengesandadaptationofaeuropeaninfluenzavaccineeffectivenessstudyplatforminresponsetothecovid19emergenceexperiencefromthedriveproject